Therefore, since KAT2A is not an essential gene for hematopoietic progenitor cells, its inhibition is proposed as a novel anti-AML therapeutic strategy and MB-3 as a potential medication for AML (94). The gene discussed is KAT2A; the disease is acute myeloid leukemia.